| A mutation of spastin is responsible for swellings and impairment of transport in a region of axon characterized by changes in microtubule composition A Tarrade, C Fassier, S Courageot, D Charvin, J Vitte, L Peris, A Thorel, ... Human molecular genetics 15 (24), 3544-3558, 2006 | 213 | 2006 |
| Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria SR Plotkin, JO Blakeley, DG Evans, CO Hanemann, TJM Hulsebos, ... American journal of medical genetics Part A 161 (3), 405-416, 2013 | 193 | 2013 |
| Deletion of Murine Smn Exon 7 Directed to Liver Leads to Severe Defect of Liver Development Associated with Iron Overload JM Vitte, B Davoult, N Roblot, M Mayer, V Joshi, S Courageot, F Tronche, ... The American journal of pathology 165 (5), 1731-1741, 2004 | 137 | 2004 |
| Refined Characterization of the Expression and Stability of the SMN Gene Products J Vitte, C Fassier, FD Tiziano, C Dalard, S Soave, N Roblot, C Brahe, ... The American journal of pathology 171 (4), 1269-1280, 2007 | 132 | 2007 |
| mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma M Giovannini, NX Bonne, J Vitte, F Chareyre, K Tanaka, R Adams, ... Neuro-oncology 16 (4), 493-504, 2014 | 90 | 2014 |
| Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease J Vitte, S Traver, A Maués De Paula, S Lesage, G Rovelli, O Corti, ... Journal of Neuropathology & Experimental Neurology 69 (9), 959, 2010 | 90* | 2010 |
| Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development J Vitte, F Gao, G Coppola, AR Judkins, M Giovannini Nature communications 8 (1), 300, 2017 | 82 | 2017 |
| Expanding the mutational spectrum of LZTR1 in schwannomatosis I Paganini, VY Chang, GL Capone, J Vitte, M Benelli, L Barbetti, R Sestini, ... European Journal of Human Genetics 23 (7), 963-968, 2015 | 77 | 2015 |
| Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 SH Isakson, AE Rizzardi, AW Coutts, DF Carlson, MN Kirstein, J Fisher, ... Communications biology 1 (1), 158, 2018 | 59 | 2018 |
| Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy M Fournier, J Vitte, J Garrigue, D Langui, JP Dullin, F Saurini, N Hanoun, ... PloS one 4 (8), e6629, 2009 | 48 | 2009 |
| Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2 K Tanaka, A Eskin, F Chareyre, WJ Jessen, J Manent, M Niwa-Kawakita, ... Clinical Cancer Research 19 (14), 3856-3870, 2013 | 42 | 2013 |
| Rac1-mediated DNA damage and inflammation promote Nf2 tumorigenesis but also limit cell-cycle progression Y Shi, SR Bollam, SM White, SZ Laughlin, GT Graham, M Wadhwa, ... Developmental cell 39 (4), 452-465, 2016 | 31 | 2016 |
| Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development MA Fuse, CT Dinh, J Vitte, J Kirkpatrick, T Mindos, SK Plati, JI Young, ... Neuro-oncology 21 (4), 486-497, 2019 | 26 | 2019 |
| Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma I Paganini, GL Capone, J Vitte, R Sestini, AL Putignano, M Giovannini, ... Journal of neuro-oncology 137, 33-38, 2018 | 16 | 2018 |
| An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth NX Bonne, J Vitte, F Chareyre, G Karapetyan, V Khankaldyyan, K Tanaka, ... Journal of neuro-oncology 129, 47-56, 2016 | 12 | 2016 |
| Linked-read sequencing analysis reveals tumor-specific genome variation landscapes in neurofibromatosis type 2 (NF2) patients DS Roberts, R Maurya, Y Takemon, J Vitte, L Gong, J Zhao, CH Wong, ... Otology & Neurotology 40 (2), e150-e159, 2019 | 5 | 2019 |
| Spinal muscular atrophy J Vitte, R Attali, N Warwar, I Gurt, J Melki Inherited Neuromuscular Diseases: Translation from Pathomechanisms to …, 2009 | 5 | 2009 |
| Cellular mechanisms of heterogeneity in NF2-mutant schwannoma C Chiasson-MacKenzie, J Vitte, CH Liu, EA Wright, EA Flynn, SL Stott, ... Nature communications 14 (1), 1559, 2023 | 4 | 2023 |
| Gene-targeted therapy for neurofibromatosis and schwannomatosis: the path to clinical trials V Staedtke, K Anstett, D Bedwell, M Giovannini, K Keeling, R Kesterson, ... Clinical Trials 21 (1), 51-66, 2024 | 2 | 2024 |
| Potential of HSP90 Inhibitors to Treat Neurofibromatosis-Related Tumors J Vitte, M Giovannini Heat Shock Protein-Based Therapies, 257-271, 2015 | 1 | 2015 |
Marco Giovannini MD PhDUCLAAdresse e-mail validée de mednet.ucla.edu
